-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Top 5 Health Care Stocks That May Dip
Top 5 Health Care Stocks That May Dip
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70.
Here's the latest list of major overbought players in this sector.
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)
- NewAmsterdam Pharma announced topline results from ROSE2 Phase 2 trial evaluating obicetrapib in combination with ezetimibe as an adjunct to high-intensity statin therapy. The company's stock has a 52-week high of $32.88 .
- RSI Value: 76.31
- NAMS Price Action: Shares of NewAmsterdam Pharma jumped 20% to settle at $13.56 on Thursday and added 4.9% in after-hours trading.
AN2 Therapeutics, Inc. (NASDAQ:ANTX)
- AN2 Therapeutics, during November, posted a Q3 loss of $0.59 per share. The company's stock has a 52-week high of $23.58.
- RSI Value: 76.53
- ANTX Price Action: Shares of AN2 Therapeutics jumped 17.5% to close at $12.31 on Thursday and added 5% in after-hours trading.
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN)
- CollPlant recently announced pre-clinical results in 3D bioprinted regenerative breast implants porcine study and full achievement of objectives. The company has a 52-week high of $14.77.
- RSI Value: 77.04
- CLGN Price Action: Shares of CollPlant Biotechnologies rose 12.9% to close at $11.21 on Thursday and added 5.4% in after-hours trading.
GlycoMimetics, Inc. (NASDAQ:GLYC)
- GlycoMimetics, last month, announced new uproleselan clinical data in both frontline unfit and treated secondary acute myeloid leukemia presented at ASH Annual Meeting. The company's 52-week high is $3.48.
- RSI Value: 71.64
- GLYC Price Action: Shares of GlycoMimetics rose 8.1% to close at $3.35 on Thursday and added 1.5% in after-hours trading.
Meihua International Medical Technologies Co., Ltd. (NASDAQ:MHUA)
- Meihua International Medical Technologies recently entered into strategic partnership with Getein Biotech Inc. to jointly produce and sell Covid-19 antigen test kits and IVDs. The company has a 52-week high of $14.94.
- RSI Value: 74.42
- MHUA Price Action: Shares of Meihua International Medical Technologies rose 9.7% to settle at $13.49 on Thursday and added 2.3% in after-hours trading.
Read More: Investor Optimism Improves Further Following GDP Report
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
医疗保健行业中最超买的股票为做空这些被高估的公司提供了机会。
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70.
RSI是一种动量指标,它比较了股票在价格上涨的日子里的强度与价格下跌时的强度。与股票的价格走势相比,它可以让交易者更好地了解股票在短期内的表现。当 RSI 高于 70 时,资产通常被视为超买。
Here's the latest list of major overbought players in this sector.
以下是该行业主要超买参与者的最新名单。
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)
新阿姆斯特丹制药公司 N.V. (纳斯达克股票代码:NAMS)
- NewAmsterdam Pharma announced topline results from ROSE2 Phase 2 trial evaluating obicetrapib in combination with ezetimibe as an adjunct to high-intensity statin therapy. The company's stock has a 52-week high of $32.88 .
- RSI Value: 76.31
- NAMS Price Action: Shares of NewAmsterdam Pharma jumped 20% to settle at $13.56 on Thursday and added 4.9% in after-hours trading.
- NewAmsterdam Pharma公布了 ROSE2 2期试验的主要结果,该试验评估了obicetrapib与依折替米贝联合用作高强度他汀类药物的辅助疗法。该公司的股票有 52 周高点 32.88 美元 。
- RSI 值: 76.31
- NAMS 价格走势: 周四,NewAmsterdam Pharma的股价上涨了20%,收于13.56美元,盘后交易中上涨了4.9%。
AN2 Therapeutics, Inc. (NASDAQ:ANTX)
AN2 Therapeutics, Inc. (纳斯达克股票代码:ANTX)
- AN2 Therapeutics, during November, posted a Q3 loss of $0.59 per share. The company's stock has a 52-week high of $23.58.
- RSI Value: 76.53
- ANTX Price Action: Shares of AN2 Therapeutics jumped 17.5% to close at $12.31 on Thursday and added 5% in after-hours trading.
- AN2 Therapeutics在11月公布了第三季度每股亏损0.59美元。该公司的 股票创下 52 周高点 的 23.58 美元。
- RSI 值: 76.53
- ANTX 价格走势: 周四,AN2 Therapeutics的股价上涨了17.5%,收于12.31美元,盘后交易中上涨了5%。
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN)
CollPlant 生物技术有限公司 (纳斯达克股票代码:CLGN)
- CollPlant recently announced pre-clinical results in 3D bioprinted regenerative breast implants porcine study and full achievement of objectives. The company has a 52-week high of $14.77.
- RSI Value: 77.04
- CLGN Price Action: Shares of CollPlant Biotechnologies rose 12.9% to close at $11.21 on Thursday and added 5.4% in after-hours trading.
- CollPlant最近公布了三维生物打印再生乳房植入物猪研究的临床前结果,并全面实现了目标。该公司有一个 52 周高点 的 14.77 美元。
- RSI 值: 77.04
- CLGN 价格走势: 周四,CollPlant Biotechnologies的股价上涨了12.9%,收于11.21美元,盘后交易中上涨了5.4%。
GlycoMimetics, Inc. (NASDAQ:GLYC)
GlycoMimetics, Inc. (纳斯达克股票代码:GLYC)
- GlycoMimetics, last month, announced new uproleselan clinical data in both frontline unfit and treated secondary acute myeloid leukemia presented at ASH Annual Meeting. The company's 52-week high is $3.48.
- RSI Value: 71.64
- GLYC Price Action: Shares of GlycoMimetics rose 8.1% to close at $3.35 on Thursday and added 1.5% in after-hours trading.
- GlycoMimetics 上个月宣布了 新的uproleselan临床数据 在ASH年会上发表的一线不适和已治疗的继发性急性髓系白血病都包括在内。该公司的52周高点为3.48美元。
- RSI 值: 71.64
- GLYC 价格走势: 周四,GlycoMimetics的股价上涨8.1%,收于3.35美元,盘后交易中上涨了1.5%。
Meihua International Medical Technologies Co., Ltd. (NASDAQ:MHUA)
梅华国际医疗科技股份有限公司 (纳斯达克股票代码:MHUA)
- Meihua International Medical Technologies recently entered into strategic partnership with Getein Biotech Inc. to jointly produce and sell Covid-19 antigen test kits and IVDs. The company has a 52-week high of $14.94.
- RSI Value: 74.42
- MHUA Price Action: Shares of Meihua International Medical Technologies rose 9.7% to settle at $13.49 on Thursday and added 2.3% in after-hours trading.
- 梅花国际医疗科技最近与Getein Biotech Inc. 建立了战略合作伙伴关系,共同生产和销售Covid-19抗原检测试剂盒和体外诊断试剂。该公司 创下 52 周新高 的 14.94 美元。
- RSI 值: 74.42
- MHUA 价格走势: 周四,梅花国际医疗科技股价上涨9.7%,收于13.49美元,盘后交易中上涨2.3%。
Read More: Investor Optimism Improves Further Following GDP Report
阅读更多: GDP报告发布后,投资者乐观情绪进一步改善
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧